Cholera vaccines help in preventing the spread of cholera disease caused by Vibrio cholerae bacterium which can cause acute diarrhea and severe dehydration if not treated on time. The vaccines boost the body's immunity against the disease making it critical for travelers visiting endemic regions.

The Global Cholera Vaccines Market is estimated to be valued at US$ 82.5 MN in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Cholera Vaccines market are Sanofi, EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD. Sanofi's live oral vaccine named Dukoral is one of the most widely used cholera vaccine across the world.

The growing prevalence of Cholera Vaccines Market Size across Asia, Africa and South America is driving significant demand for cholera vaccines from governmental and non-governmental organizations. As per WHO estimates, every year there are over 1.3 to 4 million cases and 21,000 to 143,000 deaths due to cholera globally.

Market Trends

- Growing focus on developing affordable cholera vaccines: Given the requirement of frequent booster doses with some existing vaccines, efforts are ongoing to develop affordable single-dose oral vaccines that provide long lasting protection.

- Increasing demand for multivalent oral cholera vaccines: Given the recurrence of multiple diarrheal diseases, demand is growing for multivalent oral vaccines offering protection against cholera as well as other diarrhea-causing pathogens.